Veloxis
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2000 Regency Pkwy Ste 500, Cary, North C...Phone Number
(919) 591-3090Website
www.veloxis.comRevenue
$39.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Veloxis
Founded in 2002 and based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose, is designed to enhance the absorption and bioavailability of select orally administered drugs.Explore more
Veloxis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Veloxis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Veloxis had a recent Job posting/layoffs
Check out if Veloxis is spiking on competitors!
Earning: See what the market has to say on Veloxis recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Veloxis
Funding: Get notified immidiatlly once Veloxis has new funding data
Website visits: Recent activity has been detected on your website
Check if Veloxis has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Veloxis launches new products
Veloxis, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Veloxis
Find 2 more new buyers
Compare Similar Companies to Veloxis
Compare insights from companies similar to Veloxis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Veloxis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Veloxis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Veloxis.
Veloxis financials insights
Gather financial insights about Veloxis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Stock Offering
$80.2M
2010
Stock Offering
$70.9M
2011
Grant
$626K
2018
Debt
$60M
Veloxis Tech Stack
A closer look at the technologies used by Veloxis
See more technologies
Most Recent Scoops
Hiring Plans
Veloxis has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Integrated Delivery Systems, Clinical Medicine, Healthcare Services, Health Sciences, Pharmaceutical Manufacturing, Clinical Trials, and Scientific Studies.
Hiring Plans
Person-Based
Medical Research
Person-Based
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Veloxis News & Media
Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Patients Receiving a Liver Transplant
CARY, N.C., Jan. 21, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, announced today that pegrizeprument (also known as VEL-101), a novel investigational maintenance immunosuppressive agent being...Veloxis Pharmaceuticals to Present at 2025 World Transplant Congress
CARY, N.C., July 30, 2025 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), an Asahi Kasei company and a global specialty pharmaceutical company, is pleased to announce it will present new preclinical data at the upcoming World Transplant Congress (WTC) on pegrizeprument (also...Veloxis Pharmaceuticals Receives Approval from USAN for "Pegrizeprument" as Nonproprietary Name for VEL-101
CARY, N.C., Feb. 25, 2025 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company and an Asahi Kasei company, has announced that the United States Adopted Name (USAN) Council has approved the nonproprietary (generic) name "pegrizeprument" for its...OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Veloxis
Sign Up For FreeTo access detailed company insights
Founded in 2002 and based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose, is designed to enhance the absorption and bioavailability of select orally administered drugs.... Read More
